Michael Atkin Email & Phone Number

New approaches and compounds for an old oncology target: p53.

Montreal, Quebec, Ca

Affinité is a spin-off from the Université de Montréal chemistry department, working on robust label-free detection and imaging methods that put research-level instruments on the benchtop; first product is SPR, pipeline is exciting, with future bridges towards precision diagnostics.

New Brunswick, Nj, Us

Mentoring a Rutgers NSF I-Corps national team after working with them and 4 other university technologies in a regional program early in 2023. We need to interview 100+ customers to learn if there is a fit with unmet medical needs in ADHD & binge-eating disorders for an adjuvant that mitigates stimulant challenges such as wake-promoting properties and abuse liability. If you have 15 minutes to share your thoughts, please get in touch. Thank you.

Princeton, Nj, Us

START Entrepreneur Mentor for a Princeton University technology with significant potential. Maksim Mezhericher, MSc, PhD and Prof. Howard Stone have created an innovative liquid atomization and drying technology that works at room temperature. This technology holds promise to enable room-temperature storage of certain classes of biologic. More info. on this future spin-out at: https://inaediscom.wordpress.com/

Laval, Québec, Ca

NMX uses biophysics tools and proprietary analysis knowhow to speed SAR and lead drug identification for its clients and its own research.

Kirkland, Québec, Ca

I look forward to working closely with Claude LeDuc, President and CEO of Ortho Regenerative Technologies Inc. and the Board as the company advances to its US pilot clinical trial, combining its proprietary chitosan formulation with Platelet-Rich Plasma (PRP) in treatment of rotator cuff tears versus standard of care. Ortho RTI’s proprietary technology platform possesses all the right elements to improve surgery outcomes, satisfy significant unmet medical needs and make Ortho RTI a leader in the soft tissue repair market. I look forward to benefiting from the continued counsel on the Board of Ortho's former Chairman, Steve Saviuk, who played a critical leadership role advancing Ortho RTI to its exciting position today.

Consulting in life sciences to advance early-stage technologies to critical inflection points, securing financing, collaborations and preclinical plus clinical milestones. Proven strategy development/ implementation skills. Significant biotech. business development experience includes mergers, acquisitions, licenses, sale of products and research collaborations.

Working closely with Domenic De Luca, CFO and with Scientific Founder, Larry Sutton, MD, PhD. The company focus is discovery and development of dual function, beta-lactam antibiotics for the treatment of multi-drug-resistant, bacterial infections. On June 22nd we announced a CDN$ 4.1 million financing led by Lumira Capital, with the participation of Fonds de Solidarité FTQ and SR One which participated with funds from the GlaxoSmithKline (GSK) Canada Life Sciences Innovation Fund.

Partnerships, financings and development milestones don’t happen by accident. You need to line up all the elements to close the deal. The astronomical term describing three planetary bodies in alignment is syzygy, hence SYZent Partners. Current clients include McGill University with its novel hypnotic drug discovery and development program, for which Michael successfully raised $0.9 million in financing. Michael is also working with life science companies to provide insight on licensing valuation and deal terms, and is discussing a new university assignment. .

I'm building my own life science consulting firm, helping companes and investors with strategic decisions, transitions and BD and fund raising mandates.

Ca

Lawrence Township, Nj, Us

Mba, Finance

Ba (Hons.)